Pure Global
NCT01739673

Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Cxlusa·ClinicalTrials.gov·otherCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Infectious Keratitis
Drug/Device/Intervention
Ultraviolet-A and riboflavin
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Cxlusa
Location
Scottsdale,West Hills,Littleton,Miami,Minneapolis,Saint Louis, United States of America
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2011
End date
Jul 01, 2014
Enrollment
13 participants
Primary outcome

Resolution of Signs and Symptoms of Infectious Keratitis

Summary

This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application
 (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of
 infectious keratitis.

ICD-10 classifications
KeratitisKeratitis, unspecifiedOther keratitisHerpesviral keratitis and keratoconjunctivitisKeratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01739673
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01739673 through Pure Global AI's free database. This phase not specified trial is sponsored by Cxlusa and is currently Completed. The study focuses on Infectious Keratitis. Target enrollment is 13 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.